The market for direct-to-consumer neuromodulation gadgets is booming, fueled by sophisticated marketing and patient desperation. From simple transcutaneous electrical nerve stimulation (TENS) pens to €800 ($940) ear-clip devices that stimulate the vagus nerve, these at-home, self-management tools promise a drug-free solution to chronic pain. But with rigorous scientific evidence often scarce, can these devices truly relieve patients?

“I am a little bit skeptical,” Giulia Liberati, PhD, pain researcher and associate professor at Université Catholique de Louvain, Brussels, Belgium, told Medscape Medical News. She explained that achieving consistent results with medical-grade neuromodulation devices is difficult even under ideal laboratory conditions. “I don’t understand how this could work in a home environment,” she said.

Yet, the potential of noninvasive therapy remains alluring. Jan Vesper, MD, PhD, functional neurosurgeon at the University Hospital of Düsseldorf, Düsseldorf, Germany, and vice president of the International Neuromodulation Society, is more optimistic, suggesting that for some, these devices can be a valuable, low-risk experiment. “As long as it is convenient and reasonably priced,” he said, “one can give it a try.”

The Benchmark: Clinical-Grade Neuromodulation

Neuromodulation works by influencing nervous tissue with an electrical current, either to restore a lost function or to modulate a pathologic one. The applications are specific and targeted. 

For instance, deep-brain stimulation is used for movement disorders like Parkinson’s disease, while motor cortex stimulation can address focal pain after a stroke. For refractory epilepsy, invasive vagus nerve stimulation (VNS) is an established option, and for conditions like overactive bladder, clinicians may turn to sacral nerve stimulation. All carry surgical risks, including infection and hardware migration.

These interventions are not standalone cures but part of a comprehensive, biopsychosocial model of pain management.

Adnan Al-Kaisy, MD, consultant in pain medicine at Guy’s and St Thomas’ Hospital in London, England, explained that before patients are implanted with a spinal cord stimulation device, they must undergo extensive assessment by physiotherapists and psychologists, as well as a 2-week residential rehabilitation program. “The stimulation will help with pain, but the patient needs to empower themselves, and education is fundamental,” he said, stressing that high-tech devices are just one facet of pain management.

A biopsychosocial model where “equal importance is given to physical rehabilitation, psychologic therapies, and social support” remains the gold standard in pain management, Ashley Simpson, MBChB, consultant orthopedic surgeon specializing in peripheral nerve injuries at the Royal National Orthopaedic Hospital, London, England, agreed.

The Science Behind Consumer Devices

The primary appeal of direct-to-consumer devices — including TENS pens, PENS (percutaneous electrical nerve stimulation) systems, and transcutaneous VNS (tVNS) devices — is that they are noninvasive and patient-controlled.

While the technology seems new, the principles are not. TENS and PENS are based on the gate control theory, where electrical currents are thought to block pain signals and encourage the release of endorphins. The idea of stimulating the ear to access the vagus nerve also has ancient roots: Ancient Greeks used stingrays to treat conditions like epilepsy and arthritis, while traditional Chinese medicine has long used acupuncture on the ear to modulate the body’s systems.

As Vesper explained, the skin’s high electrical impedance has historically been a barrier to effective stimulation. However, the ear has very low impedance, making it an ideal target for modern tVNS devices to deliver current to the vagus nerve’s auricular branch without requiring high intensity. This stimulation is thought to trigger anti-inflammatory reflexes and modulate central pain processing.

However, the clinical evidence supporting these mechanisms is still developing. Many studies in the field have been limited by small sample sizes and short durations. In addition, the effectiveness of these standardized devices has high patient variability.

Liberati said the research community is moving away from a one-size-fits-all approach and toward personalizing treatment by identifying individual biomarkers, such as a patient’s peak alpha frequency, and tailoring stimulation accordingly.

“Some patients respond very well, and some do not; this is the unclear aspect,” she said. “The tendency is to try to individualize these neuromodulation techniques for each patient.”

What to Tell Your Patients

What is the best advice for clinicians?

• The expert consensus leans toward caution. For most patients, Simpson said, “the recommendation would be to ‘save your money or proceed carefully.’” While the risk for physical harm is low, the risk for “financial loss, a waste of time, and disappointment” is significant, added Al-Kaisy.
• All experts agreed that these devices are, at best, adjuncts to — not replacements for — comprehensive care. The gold standard of chronic pain management remains the biopsychosocial model, combining medical, physical, and psychologic strategies tailored to the individual.
• If a patient is determined to try a device, it can be framed as a low-risk experiment. As Vesper said, noninvasive tools can sometimes serve as a predictor for the success of more invasive therapies.
• Clinicians should guide patients to question marketing claims and seek out independent, peer-reviewed research. While promising pockets of evidence are emerging, most studies are small and observational rather than randomized clinical trials.

Liberati, Al-Kaisy and Simpson reported having no relevant financial relationships. Vesper reported receiving research and travel grants from Abbott, Boston Scientific, and Medtronic. 

Manuela Callari is a freelance science journalist specializing in human and planetary health. Her work has been published in The Medical Republic, Rare Disease Advisor, The Guardian, MIT Technology Review, and others.